Radke Phillip M, Mokhtarzadeh Ali, Lee Michael S, Harrison Andrew R
Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota, USA.
Department of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA.
Neuroophthalmology. 2017 Jul 18;41(5):253-258. doi: 10.1080/01658107.2017.1318150. eCollection 2017 Oct.
The objective of this study was to observe the effect of medical cannabis in benign essential blepharospasm (BEB) as an adjunct to botulinum toxin. A retrospective chart review was performed on patients certified for medical cannabis use for BEB from September 2015 to May 2016. Patient demographics and responses, cannabis history, and severity indices were collected. Ten patients were certified for medical cannabis use. Five met the inclusion criteria, which was any patient with a diagnosis of BEB receiving standard botulinum toxin treatment who had started medical cannabis treatment by a registered distributor within the state, and was contactable by phone. Four patients discontinued use. Three out of four patients (75%) reported symptomatic improvement. Medical cannabis is an accepted therapy for muscle spastic disorders. Its potential as an adjunctive therapy for BEB remains unknown, and further investigations would be of benefit.
本研究的目的是观察医用大麻作为肉毒杆菌毒素辅助药物治疗良性原发性眼睑痉挛（BEB）的效果。对2015年9月至2016年5月期间因BEB而被认证可使用医用大麻的患者进行了回顾性病历审查。收集了患者的人口统计学信息和反应、大麻使用史以及严重程度指数。有10名患者被认证可使用医用大麻。其中5名符合纳入标准，即任何诊断为BEB且正在接受标准肉毒杆菌毒素治疗的患者，该患者已由该州的注册经销商开始医用大麻治疗，并且可以通过电话联系到。4名患者停止使用。4名患者中有3名（75%）报告症状有所改善。医用大麻是治疗肌肉痉挛性疾病的一种公认疗法。其作为BEB辅助治疗的潜力尚不清楚，进一步的研究将有益处。
